Follow the Neumora Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €284.7m. The latest transaction was reported on 21 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Aurora Daljit Singh. All data is accessible without an account.
94
Insider Decl.
n/a
Thresholds
€47m
19 ops.
Buy Volume
€2m
26 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Neumora Therapeutics, Inc. Buy (bullish), based on 7 analysts. Average price target: US$6.14.
23Σ signal
Buys €47m€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
34,987 shares@ US$1.58590.020% mcap4.3% of flowCommon StockSEC:0001610717-26-000362:12
25 of 94 declarations
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for neurological disorders. It utilizes data science-based approaches to identify new therapies.